RVMD

Revolution Medicines, Inc. RVMD

NasdaqLarge CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-644.37M

Quarter to Jun 30

Free cash flow

$-389.61M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$40.79B total
BlackRock, Inc.
$2.58B+113.6%
FARALLON CAPITAL MANAGEMENT LLC
$2.54B-0.4%
FMR LLC
$2.29B+104.0%
BAKER BROS. ADVISORS LP
$2.14B+19.8%
Darwin Global Management, Ltd.
$2.05B+380.8%
Jupiter Topco LLC
$2.01B--
VANGUARD CAPITAL MANAGEMENT LLC
$1.70B+8.7%
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.55B+10.6%
Nextech Invest, Ltd.
$1.42B0.0%
Paradigm Biocapital Advisors LP
$1.19B-4.4%
UBS Group AG
$1.02B+26.0%
STATE STREET CORP
$932.84M+295.1%
Capital World Investors
$750.66MNew
GEODE CAPITAL MANAGEMENT, LLC
$736.81M+18.1%
WELLINGTON MANAGEMENT GROUP LLP
$719.79M-36.2%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$699.65M+8711.1%
JPMORGAN CHASE & CO
$663.22M+8002.7%
BVF INC/IL
$555.32M+3.8%
Alphabet Inc.
$551.84M-10.5%
Casdin Capital, LLC
$482.68M0.0%
PRICE T ROWE ASSOCIATES INC /MD/
$453.11M-22.1%
Avoro Capital Advisors LLC
$430.18M-2.0%
NORGES BANK
$404.05M--
GOLDMAN SACHS GROUP INC
$399.49M-2.4%
Nearwater Capital Markets, Ltd
$392.73M+209.3%
See all 720 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/RVMD

Earnings Per Share

13fpro.ai/company/RVMD

Loading ratio trend…

RVMD key financials by period

Reported revenue, net income and operating margin by fiscal year, from Revolution Medicines, Inc.'s annual filings on SEC EDGAR.

Revolution Medicines, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$11.6M$-436.4M—
FY 2022$35.4M$-248.7M—
FY 2021$29.4M$-187.1M—
FY 2020$43.0M$-108.2M—
FY 2019$50.0M$-47.7M-108.1%
FY 2018$20.2M$-41.8M-200.0%
Source: RVMD filings on SEC EDGAR →

RVMD insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Revolution Medicines, Inc. (RVMD): stock profile, AI score and financials

Revolution Medicines, Inc. (RVMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. RVMD is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Revolution Medicines, Inc. reports net income of $-644.4M, free cash flow of $-389.6M. Top institutional holders of RVMD by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. RVMD trades on the Nasdaq exchange and files with the SEC under CIK 1628171. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RVMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Revolution Medicines, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1628171 →